Unlock 50% off all 2023 STAT Reports with code: 2023
STAT reports serve as indispensable tools for executives, researchers, investors, and analysts, offering seamless navigation through the intricacies of biotech, pharma, and health science. With a diverse range of relevant topics, there's a customized report awaiting you.
Elevate your understanding of the continually evolving health care landscape with STAT Reports at 50% off now through December 31st with code 2023.
EXPLORE REPORTS
OUR LATEST REPORT
In this update of STAT's bestselling report, the authors provide tools to approach clinical trial results with skepticism and critical thinking, aiming to empower readers to discern reliable research from potentially biased or misleading information.
PURCHASE NOW
MORE REPORTS UNDER $75
This STAT report is a practical guide to evaluating clinical trial delays. Whether you're a seasoned expert or a biotech newbie, this report will help you be more confident, methodical, and thoughtful the next time you're assessing a clinical trial delay.
PURCHASE NOW
Clinical trial failures are a part of life in biotech, but they don't have to mean the end of the road for promising new therapies. Biopharma consultant Frank David, M.D., Ph.D. explores the regulatory rules that give the FDA the flexibility to approve a drug and aims to help investors and biotech companies evaluate negative clinical studies to assess whether there's still a viable path to market.
PURCHASE NOW
This report is designed to help investors, researchers, patients, and others interested in the success or failure of an experimental drug navigate this uncertain terrain with clarity and data-driven insights. By doing so, you can make a clear-eyed assessment of the likelihood that a trial replicating post hoc findings will yield positive results.
PURCHASE NOW
This report is an authoritative guide to these game-changing oncology treatments, informed by STAT's original reporting and expert analysis. Get updated information about these novel therapies and an understanding of the strategies scientists are using in designing these cancer-targeting drugs.
PURCHASE NOW
No comments